Search Results - adoptive+cell+transfer

6 Results

Sort By:

Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)

Summary: NCI seeks commercial partners to co-develop and/or license a novel method to identify neoantigen reactive T cells and TCRs. Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer

Summary: The NCI seeks parties interested in research co-development and/or licensing of this combination immunotherapy approach of neoantigen-specific T cells administered alongside a neoantigen-targeting vaccine to enhance ACT and treat cancer. Description of Technology: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Sri Krishna, Zhiya Yu, Kenichi Hanada, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb

Abstract: Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient,...

Published: 4/22/2025 | Updated: 8/2/2023 | Inventor(s): Sanjivan Gautam, Yun Ji, Luca Gattinoni

Keywords(s): act, Adoptive Cell Transfer, CANCER, CAR, chimeric antigen receptor, Gattinoni, Immunotherapy, Infectious Disease, Stem Cell, T cell, T Cell Receptor, TCR

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients

Summary: NCI seeks commercial partners to co-develop and/or license a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL). Description of Technology: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Rami Yoseph, Paul Robbins, Frank Lowery, Sri Krishna, Amy Copeland, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Calcium (Ca2+) Flux-Dependent Method to Detect and Isolate Tumor Reactive T Cell Receptors (TCRs)

Abstract: T cells with T cell receptors (TCRs) for cancer-specific antigens are used for adoptive cell therapy (ACT), wherein a patient’s T cells are redirected against their own cancer. However, these isolated T cells may require further ex vivo manipulation to enhance their anti-tumor activity. The ex vivo manipulation of these T cells, or the selection...

Published: 8/5/2025 | Updated: 8/2/2023 | Inventor(s): Douglas Palmer, Anna Pasetto, Nicholas Restifo, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, CA2+, Calcium Ion, Immunotherapy, Rosenberg, T Cell Receptor, TCR, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation

Summary: The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation. Description of Technology: Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Paul Robbins, Steven Rosenberg, Gabriel Ivey, Almin Latani

Keywords(s): act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing